Olema VP reports initial stock and option holdings

Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company.

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company. As of January 30, 2026, Lu directly holds 4,488 shares of common stock and multiple stock option awards. These stock options are structured to vest monthly over multi‑year periods, with several grants featuring 25% vesting on specified initial dates and the remaining 75% vesting in equal monthly installments, all contingent on continued service with Olema.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Austin Sasha Lu

Role VP of Finance and Controller

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 138,000 contracts (Direct); Common Stock — 4,488 shares (Direct)

Footnotes (4)

1. F1. 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
2. F2. The shares underlying the option shall vest monthly over a four-year period commencing on April 3, 2023, with 1/48 of the shares vesting on the one-month anniversary of April 3, 2023 and the remainder of the shares vesting in equal installments on each one-month anniversary date thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
3. F3. 25% of the shares subject to the option vested on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date
4. F4. 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by Olema Pharmaceuticals (OLMA) report for Austin Sasha Lu?

The Form 3 reports Austin Sasha Lu’s initial ownership in Olema. It shows direct holdings of common stock and several stock option awards, each with time-based vesting schedules tied to ongoing employment with the company.

How many Olema Pharmaceuticals (OLMA) common shares does Austin Sasha Lu directly own?

Austin Sasha Lu directly owns 4,488 shares of Olema common stock. This figure is reported as the total shares of common stock held following the transactions effective on January 30, 2026, in the Form 3 filing.

What types of securities are included in Austin Sasha Lu’s Olema (OLMA) holdings?

Austin Sasha Lu’s holdings include Olema common stock and several stock option awards. The options are described as “Stock Option (Right to Buy)” and are subject to specific vesting schedules over multi‑year periods, dependent on continued service.

How do Austin Sasha Lu’s Olema (OLMA) stock options vest over time?

The stock options vest in stages over four-year periods. Some grants vest 25% on a specified date, with the remaining 75% vesting in equal monthly installments, provided Lu continues serving Olema through each vesting date.

Does the Olema (OLMA) Form 3 show any stock being bought or sold by Austin Sasha Lu?

The Form 3 does not report clear buy or sell transactions. Instead, it lists existing holdings of common stock and stock options, with transactions classified as holdings and transaction directions marked as unknown in the summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 09:33 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Austin Sasha Lu

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN STREET

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/30/2026

3. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP of Finance and Controller

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,488	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	01/25/2025	01/24/2031	Common Stock	2,000	$2.44	D
Stock Option (Right to Buy)	09/01/2025	08/31/2031	Common Stock	3,000	$2.44	D
Stock Option (Right to Buy)	02/01/2026	01/31/2032	Common Stock	13,000	$2.44	D
Stock Option (Right to Buy)	(1)	01/31/2033	Common Stock	6,500	$4.87	D
Stock Option (Right to Buy)	(2)	04/02/2033	Common Stock	17,500	$3.49	D
Stock Option (Right to Buy)	(3)	01/31/2034	Common Stock	51,000	$15.25	D
Stock Option (Right to Buy)	(4)	02/27/2035	Common Stock	45,000	$4.37	D

Explanation of Responses:

1. 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

2. The shares underlying the option shall vest monthly over a four-year period commencing on April 3, 2023, with 1/48 of the shares vesting on the one-month anniversary of April 3, 2023 and the remainder of the shares vesting in equal installments on each one-month anniversary date thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

3. 25% of the shares subject to the option vested on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date

4. 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.